Ragweed Allergy Shots: Creticos 1996 NEJM, Ragwitek, and a Lengthening Season
Ragweed allergy shots are SCIT or SLIT-tablet targeting short ragweed (Ambrosia artemisiifolia) — the dominant late-summer-to-fall pollen east of the Rockies. Creticos 1996 NEJM (n=77): significant ragweed-season upper-airway symptom reduction and improved peak flow. Ragwitek SLIT tablet is FDA-approved ages 5–65. Ragweed season has lengthened across Eastern US due to climate change (Ziska et al.). Cucurbit OAS cross-reactivity (Amb a 8/profilin) affects some patients.
7 peer-reviewed sources
Ragweed allergy shots are SCIT or Ragwitek SLIT tablet targeting Ambrosia artemisiifolia allergens. Creticos 1996 NEJM is the landmark US trial. FDA-approved SLIT tablet (Ragwitek) is ages 5–65. Climate change is lengthening ragweed season across Eastern US.
The essentials
Ragweed allergy shots are subcutaneous immunotherapy (SCIT) targeting short ragweed (Ambrosia artemisiifolia), the late-summer-to-fall pollen that drives fall hay fever across the Eastern, Midwestern, and Plains United States — and ragweed has the strongest US-conducted SCIT RCT base of any single allergen.
Curex's at-home IgE testing identifies ragweed-specific Amb a 1 sensitization with allergist review to confirm whether ragweed is the primary fall AR driver before initiating immunotherapy.
Creticos PS et al. (N Engl J Med 1996;334:501-506) randomized 77 adult asthmatic ragweed-allergic patients to short-ragweed SCIT or placebo, documenting significant reduction in ragweed-season upper-airway symptoms, improved peak flow during ragweed season, and reduced rescue medication use. The study authors cautioned that the asthma benefit alone did not justify SCIT for asthma without co-existing rhinitis — an important framing nuance. Earlier Norman and Naclerio ragweed immunotherapy work established rhinitis efficacy precedent that the Creticos trial built upon.
Ragweed major allergens: Amb a 1 is the primary sensitizer in 90%+ of ragweed-allergic patients (38 kDa pectate lyase). Amb a 1 is among the 19 FDA-standardized US allergen extracts (CBER), giving ragweed SCIT a standardized potency anchor not available for many other allergens. Amb a 6 and Amb a 11 are additional components.
The FDA-approved SLIT alternative: Ragwitek (short ragweed SLIT tablet, Merck) was FDA-approved in 2014 for adults 18–65 and expanded in April 2021 to include ages 5–17 (now FDA-approved ages 5–65). It is a daily sublingual tablet taken at home after one supervised first-dose clinic visit. Ragwitek carries a boxed warning for anaphylaxis, requires a supervised first dose in a medical setting, and requires co-prescription of an epinephrine auto-injector. The choice between SCIT and Ragwitek SLIT depends on sensitization profile — Ragwitek is designed for ragweed monosensitization or ragweed-dominant polysensitization; SCIT accommodates any combination of allergens in one vial.
Climate change is now a material clinical variable for ragweed counseling. Peer-reviewed aerobiology research (Ziska et al., PNAS series) has documented ragweed season lengthening across the Eastern US due to later first-frost dates and increased CO2 promoting greater pollen production per plant. Patients whose ragweed season was 8 weeks a decade ago are now often contending with 10–12 week seasons — changing the cost-benefit math on a 3-to-5-year disease-modifying investment versus annual pharmacotherapy escalation.
Geographic distribution: ragweed is predominantly east of the Rocky Mountains. California and the Pacific Northwest have minimal native short ragweed (Ambrosia artemisiifolia) exposure, though Roman wormwood (Ambrosia trifida) and other weed pollens may cause similar symptoms in the West. Ragweed is dominant in the Midwest, Plains, Northeast, and Southeast — peak season late August through October in most regions.
Cucurbit OAS / ragweed-melon syndrome: Amb a 8 (profilin) and other panallergens cross-react with melons, bananas, cucumbers, zucchini, and other cucurbits. Ragweed-sensitized patients sometimes report oral pruritus on raw cucumber, cantaloupe, or banana ingestion — classic profilin-mediated OAS. This is a cross-reactive phenomenon, not a separate food allergy, and does not typically respond as predictably to ragweed SCIT as the Bet v 1 PR-10 food OAS does to birch SCIT.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Ragweed SCIT is anchored by the strongest US-conducted single-allergen RCT in the immunotherapy literature.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
Does ragweed SCIT use the same extract as the Ragwitek tablet?
Ragwitek (Merck) is a standardized SLIT tablet formulation of short ragweed Amb a 1 specifically manufactured for sublingual delivery. The SCIT extract for short ragweed is a liquid aqueous preparation of standardized short-ragweed extract for subcutaneous injection. Both target Amb a 1 — the same major allergen in 90%+ of ragweed-sensitized patients. The product formulations, routes, and clinical protocols are different, but the immunologic target is the same FDA-standardized short ragweed allergen. Whether to use SCIT or the Ragwitek SLIT tablet depends on the patient's full sensitization profile, lifestyle preferences, and allergist recommendation.
Is ragweed only in certain parts of the United States?
Short ragweed (Ambrosia artemisiifolia) is predominantly east of the Rocky Mountains — concentrated in the Midwest, Plains, Northeast, and Southeast. California and the Pacific Northwest have minimal native short ragweed exposure. In Texas and the Southwest, other weeds (e.g., mixed weed pollen from Ambrosia-related and other Asteraceae species) may contribute, though ragweed sensitization patterns differ from the Eastern US. Ragweed season varies by latitude: earlier peak in the Southeast (late July to August), later peak in the Northeast (September through October). Ragweed grows prolifically in disturbed soils — roadsides, vacant lots, construction sites — which contributes to high urban exposure.
What is the ragweed-melon syndrome?
Ragweed-melon syndrome (also called cucurbit oral allergy syndrome) is oral pruritus and mild oral-mucosal swelling triggered by raw melon, cantaloupe, watermelon, cucumber, zucchini, or banana in ragweed-sensitized patients. The mechanism is profilin (Amb a 8 in ragweed) cross-reactivity with profilin homologs in cucurbit fruits and banana — a panallergen family that is heat-labile and typically does not produce systemic reactions. This is distinct from a true food allergy and does not carry the same anaphylaxis risk. Cooking or processing the cucurbit destroys the profilin cross-reactive epitope. Ragweed SCIT does not reliably or predictably resolve cucurbit OAS.
How has climate change affected ragweed allergy?
Peer-reviewed aerobiology research (Ziska et al., PNAS series and related literature) has documented that ragweed season has lengthened across the Eastern US over recent decades due to: (1) later autumn first-frost dates allowing ragweed plants to produce pollen longer; (2) elevated atmospheric CO2 promoting increased pollen production per plant. Patients in the Eastern US who had 8-week ragweed seasons historically are now contending with 10–12 week seasons in many regions. This changes the cost-benefit analysis for immunotherapy: a 3-to-5-year SCIT or SLIT course delivering 3–12 years of post-treatment benefit is increasingly compelling compared to taking escalating daily medication through a lengthening fall season indefinitely.
Can children get ragweed allergy shots?
Yes. Both ragweed SCIT and the Ragwitek SLIT tablet are appropriate for children. Cox 2011 PP3 supports SCIT in children aged 5 and older. Ragwitek was expanded to ages 5–17 in April 2021 and is now approved for ages 5–65. The pediatric PAT study (Möller 2002 JACI, Jacobsen 2007 Allergy) documented that pollen SCIT (grass and birch in the original cohort; generalizable mechanistically to ragweed) halved asthma incidence at 10-year follow-up, making the pediatric immunotherapy case for ragweed particularly strong in regions where ragweed dominates the fall pollen season.
What is the Creticos 1996 NEJM study and why does it matter?
Creticos PS et al. (N Engl J Med 1996;334:501-506, DOI: 10.1056/NEJM199602223340804) randomized 77 adult asthmatic ragweed-allergic patients to short-ragweed SCIT or placebo in a double-blind trial. The trial documented significant reduction in ragweed-season upper-airway symptoms, improved peak expiratory flow during ragweed season, and reduced rescue medication use in the SCIT group. It is the landmark US-conducted RCT for ragweed immunotherapy — the equivalent of Walker 2001 for grass and Bødtger 2002 for birch. The trial's cautionary note — that asthma benefit alone without rhinitis co-improvement did not justify SCIT — remains clinically relevant guidance for patient selection.
What are the side effects of ragweed allergy shots?
Ragweed SCIT follows the same reaction profile as all pollen SCIT. Local reactions at the injection site occur in approximately 78–82% of patients at some point during treatment (Calabria/Tankersley LOCAL study, JACI 2009) and approximately 16% of individual injections; large local reactions (greater than 25mm persisting over 24 hours) at 0.4% of injections. Systemic reactions occur in approximately 0.1% of injections and 1.9% of patients (Epstein 2014). Approximately 70% of systemic reactions appear within 30 minutes of injection — the clinical basis for the post-injection observation window used in both clinic and at-home protocols. With Curex at-home shots, a prescribed epinephrine auto-injector is confirmed on-hand before your first dose, and every dose change is supervised live over Zoom. If you experience throat tightness, difficulty breathing, generalized hives, or lightheadedness, use your prescribed epinephrine auto-injector immediately and call 911.
Related Articles
Allergy Vaccine: WHO Term for SCIT Explained | Curex
Allergy vaccine (WHO 1998) = allergen immunotherapy (SCIT/SLIT). No branded product — serums custom-compounded. At-home SCIT from Curex at $129/mo.
Read moreAre There Seasonal Allergy Shots? Yes — 3 Types | Curex
Yes — seasonal allergy shots exist as SCIT, SLIT tablets, or depot steroid. Curex at-home SCIT ($129/mo) covers tree, grass, and weed pollen.
Read moreAllergy Shots Pollen — Top-Funnel Guide | Curex
Allergy shots for pollen are SCIT targeting your specific IgE-sensitized pollens. Cochrane 51 RCTs: symptom SMD −0.73. 60–80 injections over 3–5 years. Full beginner guide.
Read moreAllergy Shots vs Drops: Evidence-Based Comparison | Curex
Allergy shots (SCIT) vs sublingual drops (SLIT): comparable efficacy per Nelson 2015, but SLIT has zero fatalities vs 1 per 2.5M shots. Full comparison.
Read moreAllergy Shot Schedule: Full Timeline Guide | Curex
Allergy shot schedule: weekly build-up 24–28 wks, maintenance every 2–4 wks × 3–5 yrs (Cox 2011). Cluster, rush variants and at-home option explained.
Read moreSeasonal Allergy Shots Schedule & Count | Curex Guide
Seasonal allergy shots total 60–80 injections over 3–5 years. Cox 2011: 39 Year-1 visits. Learn the schedule mechanics and why adherence drops after visit one.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.